IGC professor named among UK's 50 future innovators

Professor Asier Unciti-Broceta has been named one of 50 Future Innovators by Universities UK for his discovery of the cancer drug NXP900.

Head shot of Asier Unciti-Broceta with 50 Future Innovators text

NXP900 targets the cancer-linked protein SRC which is involved in around half of all cancers. It is the first drug to lock SRC fully into its inactive state, shutting down all its functions. 

After Professor Unciti-Broceta published his findings in 2021, the University of Edinburgh licensed it to Nuvectis Pharma, and it entered clinical trials in 2023. Early trials show it is well tolerated, and it could offer new hope for patients with advanced and treatment-resistant cancers. 

He is one of 50 Future Innovators recognised as part of Universities UK's Future Universities campaign, which celebrates 50 people across the UK whose work has been shaped by a UK university. 

He was selected alongside University colleagues Stephen Wallace, Yunjie Yang and Michaela Thorne (jointly with Robert Gordon University).

The final 50 were chosen by independent expert judges, including Baroness Martha Lane Fox and Dr Anne-Marie Imafidon, for work that is genuinely new and has the potential to change people's lives.

I'm thrilled to have been named one of the 50 Future Innovators by Universities UK.

My research was profoundly influenced by being part of the University of Edinburgh. Discovering our clinical drug candidate, NXP900, required a research environment that champions bold, unconventional thinking and seamless academic teamwork. The College of Medicine and the Institute of Genetics and Cancer provided the ideal, diverse ecosystem to find a drug that challenged the state-of-the-art and to translate this exciting discovery into a promising life-saving treatment.

Related Links

Tags

2026